Company:  CNS PHARMACEUTICALS, INC. (CNSP)
Form Type:  3
Filing Date:  11/8/2019 
CIK:  0001729427 
Address:  2100 WEST LOOP SOUTH
SUITE 900
 
City, State, Zip:  HOUSTON, Texas 77027 
Telephone:  1-800-946-9185 X701 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$1.68  
Change: 
-0.1084 (-6.06%)  
Trade Time: 
03:52 PM EST  
Market Cap: 
$28.01M
Trade CNSP now with 

© 2020  
Description of Business
We are a preclinical stage pharmaceutical company organized as a Nevada corporation in July 2017 to focus on the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors, based on intellectual property that we license under a license agreements with HPI and the University of Texas M.D. Anderson Cancer Center and pursuant to a collaboration and asset purchase agreement with Reata. We believe our lead drug candidate, Berubicin, if approved by the FDA, may be a significant discovery in the treatment of glioblastoma. Glioblastoma are tumors that arise from astrocytes, which are star-shaped cells making up the supportive tissue of the brain. These tumors are usually highly malignant (cancerous) because the cells reproduce quickly and they are supported by a large network of blood vessels. Berubicin is an anthracycline, which is a class of drugs that are among the most powerful chemotherapy drugs known.
Register and access this filing in:     
  FORM 3
    NAME AND TITLE
    NON DERIVATIVE SECURITIES
    DERIVATIVE SECURITIES
    EXPLANATIONS AND REMARKS
    REPORTING OWNERS
    SIGNATURES
  EXHIBIT 24.1